The Relationships Between Subclinical Hypertensive Target Organ Damage And Th17 Cells

Objective:By detecting the proportion of Th17 cells in peripheral blood,related cytokines and key transcription factors in hypertensive patients with subclinical target organ damage(TOD),without subclinical TOD and normal controls,we explored the relationship between Th17 cells and the subclinical TOD of hypertension,and to explore the role of Th17 cells in the pathogenesis of hypertension subclinical TOD.Methods: A total of 179 patients with essential hypertension admitted to the Department of Cardiology,Tianjin Medical University General Hospital from September 2015 to September 2017 were selected and divided into two groups based on the presence or absence of subclinical target organ damage: Sub-clinical TOD group 92 Cases,no subclinical TOD group 87 cases.Sixty-three patients in the control group had undergone sub-clinical TOD screening for hypertension in the physical examination patients who were present at the physical examination center of our hospital during the same period.No abnormalities were observed.Determination of the proportion of Th17 cells labeled with CD3+CD4+IL-17A+/CD3+CD4+ in peripheral blood by flow cytometry(Th17cell/CD3+CD4+cells);a quantitative method of enzyme linked immunosorbent assay was used to detect the concentration of IL-23 and IL-17 in the plasma of peripheral blood;total mRNA in peripheral blood mononuclear cell(PBMNC)was extracted and cDNA was obtained by reverse transcription.YBRGreen? real-time fluorescence quantitative polymerase chain reaction(RT-PCR)was used to detect the expression level of IL-17 and key transcription factors ROR?t and STAT-3 mRNA of Th17 cells.Results: The proportion of Th17 cells in sub-clinical TOD patients with high blood pressure(2.94±1.08)was higher than those without subclinical TOD hypertension(1.35± 0.29)and normal controls(0.61 ± 0.46)(P<0.05),while the normal control group(0.61 ± 0.46)was lower than that in the group without subclinical TOD hypertension(1.35 ± 0.29).There was a difference between the two groups(P = 0.023).The plasma IL-17 concentration in hypertensive subclinical TOD group(34.52±19.01)was higher than that in non-subclinical TOD hypertension group(21.17 ± 9.07)and normal population control group(14.05±6.32),P=0.034,hypertension subclinical The plasma IL-17 concentration in the TOD group(34.52 ± 19.01)was higher than that in thesubclinical TOD hypertensive group(21.17±9.07).P=0.031 was statistically significant.The plasma concentration of IL-23 in hypertensive subclinical TOD group(275.65 ±283.50)was higher than that in non-subclinical TOD hypertension group(221.03 ±169.70)and normal population control group(140.10 ± 56.59),P=0.017,subclinical hypertension The plasma IL-23(275.65±283.50)was slightly higher in the TOD group than in the subclinical TOD hypertensive group(221.03±169.70),P=0.07.There was no significant difference between the two groups.The plasma concentration of IL-23 in patients without subclinical TOD hypertension(221.03±169.70)was higher than that in the normal population(140.10±56.59),and the P=0.046 concentration was statistically significant.The relative mRNA expression level of IL-17 in PBMNC subgroup of hypertension sub-clinical TOD group(11.23 ± 4.24)was higher than that in non-subclinical TOD hypertension group(8.43 ± 0.75)and normal population control group(5.06 ± 1.41),P=0.032 At the same time,there was a significant difference between sub-clinical TOD hypertension group(11.23±4.24)and non-subclinical TOD hypertension group(8.43 ± 0.75),P<0.001,and there was no subclinical TOD hypertensive patient group IL-17 The relative expression of mRNA(8.43 ±0.75)was significantly higher than that in the normal population(5.06 ±1.41),P<0.001,with a statistically significant difference.The relative expression of ROR ? t mRNA in the sub-clinical TOD group of hypertensive patients with PBMNC(1.06 ± 0.57)was significantly higher than that in the non-hypertension sub-clinical TOD group(0.540±0.110)and the normal control group(0.05 ± 0.06),P=0.021,while the There was a difference between the sub-clinical TOD group(1.06±0.57)and the sub-clinical TOD hypertensive group(0.54±0.11),P=0.043,and no relative ROR?t mRNA expression in the subclinical TOD hypertensive group(0.54±0.11).)Higher than the normal group(0.05 ± 0.06),P = 0.027,the difference was statistically significant.The relative expression of STAT-3 mRNA in PBMNC in the hypertensive subclinical TOD group(2.90±1.27)was higher than that in the subclinical TOD hypertensive group(1.62±0.23)and in the normal control group(1.15 ± 0.35),P=0.033 The difference was statistically significant between the sub-clinical TOD hypertension group(2.90±1.27)and the sub-clinical TOD hypertensive patient group(1.62 ± 0.23),P=0.037 and no subclinical TOD hypertensive patient group The relative expression level of STAT-3mRNA(1.62±0.23)was higher than that of the normal group(1.15±0.35),P=0.053.The difference was not statistically significant.Conclusions: The percentage of Th17 cells,IL-23 and IL-17 levels in peripheral blood of hypertensive patients with subclinical TOD were increased,IL-17 mRNA and key transcription factors ROR?t,STAT-3 expression levels were increased,suggesting that Th17 cells and their related cytokines may be involved in the subclinical TOD formation of hypertension.